News

Less May Be More in Treating High-Risk Myeloma

View on the News

Begin With the End Point in Mind

"This is an intriguing observation," Dr. Martha Q. Lacy said in a separate interview. "The author points out that it is a retrospective study, and results could be confounded by a number of variables, so I agree that one cannot take this as the definitive word on this subject. This should be studied in well-designed prospective studies. It also underscores the need to design trials with overall survival as the primary end point.

"Increasingly, myeloma studies have used remission rates and progression-free survival as primary end points," she said. "If studies are not designed with overall survival as the end point, we risk missing potentially critical insights into the best treatment strategies."

Dr. Lacy is with the hematology division at the Mayo Clinic in Rochester, Minn.


 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY

*CLARIFICATION 1/23/12 The status of bortezomib and lenalidomide in treatment for multiple myeloma was clarified in this sentence.

Pages

Recommended Reading

Heparin Bridging Associated With Increased Bleeding Risk
MDedge Internal Medicine
IGF-I Doesn't Predict Late Complications in Childhood Cancer Survivors
MDedge Internal Medicine
Fondaparinux Reduces Events From Superficial Vein Thromboses
MDedge Internal Medicine
Old Antivirals Rival New for Cancer Prevention in Hepatitis B
MDedge Internal Medicine
Pregnant Women With Lymphoma Can Have Good Outcomes
MDedge Internal Medicine
Many Elderly AML Patients Not Receiving Chemotherapy
MDedge Internal Medicine
FDA: Rare Brain Infection Prompts Boxed Warning for Brentuximab
MDedge Internal Medicine
Biomarkers May Improve Lung Cancer Screening
MDedge Internal Medicine
Glucarpidase Approved to Treat Methotrexate Toxicity
MDedge Internal Medicine
Regorafenib Anticipated to Show Survival Advantage in Colorectal Cancer
MDedge Internal Medicine